{"title":"mRNA Reagents","description":"\u003cp\u003eSynthetic, in vitro–transcribed (IVT) mRNAs encoding reporters, cytokines, growth factors, recombinases, and immunotherapy targets for transient protein expression in mammalian cells.\u003c\/p\u003e","products":[{"product_id":"ccr4-bhn20152463","title":"CCR4","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCCR4\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631446381,"sku":"IR0018002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239635575149,"sku":"IR0018010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239635607917,"sku":"IR0018020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239635640685,"sku":"IR0018050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239635673453,"sku":"IR0018100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239635706221,"sku":"IR0018500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_537a86a7-1d8c-4854-abfd-f9785bd72ed7.png?v=1776677729"},{"product_id":"cd247-cd3-zeta-bhn20152467","title":"CD247 (CD3 zeta)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD247 (CD3 zeta)\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631479149,"sku":"IR0022002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239652188525,"sku":"IR0022010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239652221293,"sku":"IR0022020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239652254061,"sku":"IR0022050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239652286829,"sku":"IR0022100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239652319597,"sku":"IR0022500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_10a044c4-5fd9-4451-8062-c0a08742b044.png?v=1776677730"},{"product_id":"mcherry-pa-bhn20152457","title":"mCherry-PA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003emCherry-PA\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631544685,"sku":"IR0012002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239649173869,"sku":"IR0012010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239649206637,"sku":"IR0012020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239649239405,"sku":"IR0012050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239649272173,"sku":"IR0012100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239649304941,"sku":"IR0012500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_62813589-52ec-4fb3-b71c-1dcfafd48459.png?v=1776677726"},{"product_id":"mscarlet3-bhn20152459","title":"mScarlet3","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003emScarlet3\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631511917,"sku":"IR0014002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239649665389,"sku":"IR0014010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239649698157,"sku":"IR0014020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239649730925,"sku":"IR0014050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239649763693,"sku":"IR0014100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239649796461,"sku":"IR0014500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_a244643f-fb22-4a44-81f9-665586d7cb20.png?v=1776677730"},{"product_id":"egfp-cy5-bhn20152450","title":"EGFP(Cy5)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eEGFP(Cy5)\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631577453,"sku":"IR0005002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239649010029,"sku":"IR0005010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239649042797,"sku":"IR0005020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239649075565,"sku":"IR0005050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239649108333,"sku":"IR0005100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239649141101,"sku":"IR0005500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_e2e00b1e-8e10-4663-ad18-436a62409d4e.png?v=1776677729"},{"product_id":"ova-bhn20152448","title":"OVA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eOVA\u003c\/strong\u003e, a immunogen construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eImmunogen mRNAs encode antigenic proteins intended to stimulate immune responses in experimental models or to serve as reference antigens for antibody production and validation workflows. Ovalbumin (OVA) is a well-characterised model antigen extensively used in immunology research to study antigen presentation, T-cell activation, and tolerance induction. Keyhole limpet hemocyanin (KLH\/Hemocyanin) is a carrier protein commonly conjugated to haptens or used as an adjuvant to enhance humoral immunity. Delivering these antigens via mRNA allows dose-controlled, transient antigen expression in defined cell populations, making it compatible with therapeutic antigen-presentation studies.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eTherapeutic vaccine development: mRNA immunogen platforms have demonstrated clinical proof-of-concept with approved COVID-19 vaccines; OVA-mRNA systems are widely used in preclinical immunotherapy and tolerisation studies.\u003c\/li\u003e\n  \u003cli\u003eAntigen-presenting cell transfection: mRNA-encoded antigens are used to transiently load dendritic cells for stimulation assays and adoptive transfer experiments without lentiviral safety constraints.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003ePreclinical antigen challenge — OVA mRNA in immunisation and tolerance induction studies in primary dendritic cells and T-cell co-culture systems.\u003c\/li\u003e\n  \u003cli\u003eAntibody production support — mRNA-based antigen expression for immunisation or cell-based antigen presentation, reducing dependence on recombinant protein purification.\u003c\/li\u003e\n  \u003cli\u003eModel antigen benchmark — OVA is a widely used reference antigen for validating new adjuvants, delivery systems, or immune modulation approaches.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eOVA mRNA expression levels in transfected cells may not be equivalent to recombinant protein concentrations; quantify expressed antigen by ELISA or immunoblot before use in immunisation experiments.\u003c\/li\u003e\n  \u003cli\u003eImmunogenicity of mRNA-expressed antigens depends on delivery vehicle, dose, and cell type; validate antigen presentation in the intended cell system (e.g., bone marrow-derived DCs) before in vivo or functional studies.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631610221,"sku":"IR0003002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239637705069,"sku":"IR0003010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239637737837,"sku":"IR0003020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239637770605,"sku":"IR0003050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239637803373,"sku":"IR0003100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239637836141,"sku":"IR0003500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_f3347e08-e781-4938-92af-3b522c59ffd1.png?v=1776677731"},{"product_id":"egfp-pa-bhn20152455","title":"EGFP-PA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eEGFP-PA\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631642989,"sku":"IR0010002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239636722029,"sku":"IR0010010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239636754797,"sku":"IR0010020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239636787565,"sku":"IR0010050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239636820333,"sku":"IR0010100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239636853101,"sku":"IR0010500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_5a26de20-3e5a-4a78-90b6-5a84e7f2ca89.png?v=1776677729"},{"product_id":"firefly-luciferase-bhn20152453","title":"Firefly Luciferase","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eFirefly Luciferase\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631675757,"sku":"IR0008002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239636885869,"sku":"IR0008010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239636918637,"sku":"IR0008020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239636951405,"sku":"IR0008050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239636984173,"sku":"IR0008100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239637016941,"sku":"IR0008500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_a16920b8-0140-4e3c-b1cf-44de7bf56dbe.png?v=1776677730"},{"product_id":"cd80-bhn20152477","title":"CD80","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD80\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631708525,"sku":"IR0032002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239646028141,"sku":"IR0032010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239646060909,"sku":"IR0032020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239646093677,"sku":"IR0032050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239646126445,"sku":"IR0032100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239646159213,"sku":"IR0032500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_e40e2252-054e-4f56-ab31-6ca6dd49dc37.png?v=1776677726"},{"product_id":"pd-l1-cd274-bhn20152506","title":"PD-L1 (CD274)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003ePD-L1 (CD274)\u003c\/strong\u003e, a membrane protein, immune checkpoints construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eImmune checkpoint molecules are co-inhibitory or co-stimulatory receptors that regulate the magnitude and duration of immune responses. Checkpoint blockade — inhibiting pathways such as PD-1\/PD-L1 and CTLA-4 — has transformed clinical oncology. mRNA-based expression of checkpoint proteins on cell surfaces provides a physiologically relevant model for antibody binding studies, receptor-ligand blocking assays, and mechanistic validation of checkpoint inhibitor candidates. Because the protein is expressed from endogenous translational machinery, the surface presentation better mimics native post-translational modifications compared to ectodomain recombinant proteins.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCheckpoint blockade mechanism studies: PD-1, PD-L1, and TIGIT mRNA expression enables cell-based co-culture assays to study how checkpoint inhibitory antibodies restore T-cell effector function.\u003c\/li\u003e\n  \u003cli\u003eBinding affinity characterisation: mRNA-expressed native checkpoint proteins on cell surfaces are used in flow-based antibody kinetic binding assays that are difficult to replicate with ectodomain fusion proteins.\u003c\/li\u003e\n  \u003cli\u003eCombinatorial checkpoint immunotherapy: mRNA co-expression of multiple checkpoint ligands models the complex immunosuppressive tumour microenvironment for multi-target blockade studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCheckpoint blockade functional assays — co-culture of mRNA-expressed PD-L1 or TIGIT cells with primary T cells to measure blockade-mediated restoration of T-cell function.\u003c\/li\u003e\n  \u003cli\u003eAntibody binding and blocking studies — flow cytometry-based competitive binding and blocking assays using checkpoint protein-expressing target cells.\u003c\/li\u003e\n  \u003cli\u003eMechanistic studies in exhaustion models — transient checkpoint expression in activation-suppression co-culture systems to model T-cell exhaustion and reinvigoration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003ePD-L1 mRNA expression may be influenced by endogenous IFN-γ signalling in some cell lines; confirm that expression is driven primarily by transfected mRNA rather than endogenous upregulation.\u003c\/li\u003e\n  \u003cli\u003eCheckpoint protein binding assays require careful antibody selection; some therapeutic antibody clones target specific epitopes that may be partially occluded in the mRNA-expressed cell surface context.\u003c\/li\u003e\n  \u003cli\u003eTIGIT–PVR interaction studies benefit from expressing both receptor and ligand in the co-culture system; ensure surface expression of both partners is confirmed before running blocking assays.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631741293,"sku":"IR0061002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239651533165,"sku":"IR0061010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239651565933,"sku":"IR0061020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239651598701,"sku":"IR0061050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239651631469,"sku":"IR0061100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239651664237,"sku":"IR0061500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_806af9bd-1f74-46fc-a68f-bdbb12cc305b.png?v=1776677730"},{"product_id":"baff-bhn20152513","title":"BAFF","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eBAFF\u003c\/strong\u003e, a cytokines construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCytokines are a broad class of small secreted proteins that mediate intercellular communication within the immune system and across a range of tissue types. They include interleukins (ILs), interferons (IFNs), tumour necrosis factors (TNFs), and colony-stimulating factors (CSFs), each acting through cognate receptors to modulate immune activation, inflammation, haematopoiesis, and cell survival. mRNA-encoded cytokines are increasingly employed in immuno-oncology research as reference standards for neutralisation assays, antibody validation, receptor-binding studies, and bioassay development. Transient cytokine expression via mRNA avoids the chromosomal integration concerns associated with viral vector approaches and allows rapid, reversible functional evaluation.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eImmuno-oncology bioassay standards: Cytokine mRNAs expressed in reporter cell lines are used as reference materials for neutralising antibody potency assays and ELISA calibration in therapeutic antibody development.\u003c\/li\u003e\n  \u003cli\u003eCAR T-cell armoured constructs: mRNA-encoded cytokines (e.g., IL-15, IL-21) are being evaluated in combination with CAR constructs to improve T-cell persistence in solid tumour microenvironments.\u003c\/li\u003e\n  \u003cli\u003eInflammation modelling: Transient cytokine mRNA transfection allows controlled induction of inflammatory gene signatures in primary macrophages and dendritic cells for mechanistic pathway studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eNeutralisation assay standards — mRNA-expressed cytokines used as reference materials for potency and neutralisation testing of therapeutic antibodies in reporter-cell or bioassay formats.\u003c\/li\u003e\n  \u003cli\u003eReceptor binding validation — cell-surface expressed cytokine receptors or secreted cytokine ligands used in SPR, flow cytometry, and ELISA-based binding studies.\u003c\/li\u003e\n  \u003cli\u003eImmune cell activation studies — transient cytokine mRNA expression in primary immune cells (T cells, macrophages, NK cells) to dissect signalling pathways and transcriptional responses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCytokine secretion levels from transfected cells may vary with mRNA dose, cell type, and transfection efficiency; always quantify secreted protein by ELISA or bioassay before use as a standard.\u003c\/li\u003e\n  \u003cli\u003eFor neutralisation assays, confirm that the mRNA-expressed cytokine is biologically active (e.g., STAT signalling reporter) before using it as a reference antigen.\u003c\/li\u003e\n  \u003cli\u003eCytokine-encoding mRNAs can activate innate immune pathways in sensitive primary cells despite N1-Me-Pseudo UTP modification; include matched negative control mRNA (e.g., EGFP mRNA) at equivalent doses.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631774061,"sku":"IR0068002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239637868909,"sku":"IR0068010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239637901677,"sku":"IR0068020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239637934445,"sku":"IR0068050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239637967213,"sku":"IR0068100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239637999981,"sku":"IR0068500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_d85586d1-66d2-4a09-89f9-2ce3c1985aa4.png?v=1776677730"},{"product_id":"bcma-tnfrsf17-bhn20152473","title":"BCMA (TNFRSF17)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eBCMA (TNFRSF17)\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631806829,"sku":"IR0028002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239648649581,"sku":"IR0028010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239648682349,"sku":"IR0028020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239648715117,"sku":"IR0028050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239648747885,"sku":"IR0028100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239648780653,"sku":"IR0028500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_f8dda8dd-ab68-4282-9396-6500d36a5eee.png?v=1776677729"},{"product_id":"ang2-bhn20152510","title":"ANG2","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eANG2\u003c\/strong\u003e, a growth factor construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eGrowth factors are secreted or membrane-bound polypeptides that regulate cell proliferation, survival, differentiation, and migration by binding to specific cell-surface receptors and activating downstream signalling cascades (e.g., MAPK\/ERK, PI3K\/AKT, JAK\/STAT). mRNA-based delivery of growth factors enables transient, dose-controlled protein expression in target cells without the need for stable genomic integration. This approach is particularly relevant for ex vivo cell expansion protocols, stem cell differentiation studies, and functional receptor-ligand binding assays, where precise temporal control of growth factor availability is required.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eEx vivo cell manufacturing: Transient mRNA expression of growth factors such as SCF, FLT3L, and TPO is being investigated for short-window stimulation of HSC expansion without chronic cytokine exposure that risks differentiation bias.\u003c\/li\u003e\n  \u003cli\u003eReceptor-ligand interaction studies: Growth factor mRNA provides native-topology ligands for SPR, BLI, and cell-based binding assays validating therapeutic antibody epitopes on receptor ectodomains.\u003c\/li\u003e\n  \u003cli\u003eTissue engineering scaffolds: Growth factor mRNA is incorporated into hydrogel and scaffold matrices to achieve controlled spatiotemporal protein release in tissue-regeneration models.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReceptor activation assays — transient growth factor mRNA expression stimulates cognate receptors in cell-based reporter assays to characterise ligand-receptor interactions.\u003c\/li\u003e\n  \u003cli\u003eEx vivo cell expansion — short-duration growth factor mRNA pulses to stimulate haematopoietic or stem cell expansion without chronic cytokine exposure.\u003c\/li\u003e\n  \u003cli\u003eAntibody neutralisation studies — mRNA-expressed secreted growth factors as target antigens in neutralisation bioassays validating anti-growth-factor therapeutic antibodies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSecreted growth factors expressed from transfected cells are present in conditioned media; ensure downstream assays account for the actual secreted protein concentration rather than mRNA input dose.\u003c\/li\u003e\n  \u003cli\u003eGrowth factor receptor expression on the target cell must be confirmed; absence of receptor expression on the transfected cell line may result in undetectable signalling readouts.\u003c\/li\u003e\n  \u003cli\u003eTransient expression windows are typically 24–72 h post-transfection for lyophilised mRNA; titrate dose and time-point empirically for the specific growth factor and cell type.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631839597,"sku":"IR0065002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239644062061,"sku":"IR0065010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239644094829,"sku":"IR0065020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239644127597,"sku":"IR0065050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239644160365,"sku":"IR0065100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239644193133,"sku":"IR0065500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_fc1cf0c1-852a-4530-9183-4efc3b333b85.png?v=1776677731"},{"product_id":"ret-bhn20152485","title":"RET","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eRET\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631872365,"sku":"IR0040002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239647502701,"sku":"IR0040010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239647535469,"sku":"IR0040020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239647568237,"sku":"IR0040050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239647601005,"sku":"IR0040100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239647633773,"sku":"IR0040500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_ecc84bed-c9af-46ce-8e33-8a91dd040209.png?v=1776677731"},{"product_id":"egfr-bhn20152481","title":"EGFR","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eEGFR\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631937901,"sku":"IR0036002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239644881261,"sku":"IR0036010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239644914029,"sku":"IR0036020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239644946797,"sku":"IR0036050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239644979565,"sku":"IR0036100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239645012333,"sku":"IR0036500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_479fafca-3e67-4455-a713-79a3af2f2979.png?v=1776677728"},{"product_id":"cd3e-bhn20152466","title":"CD3E","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD3E\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631905133,"sku":"IR0021002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239638688109,"sku":"IR0021010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239638720877,"sku":"IR0021020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239638753645,"sku":"IR0021050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239638786413,"sku":"IR0021100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239638819181,"sku":"IR0021500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_c40b1463-ce21-4727-ac1c-b4126508222a.png?v=1776677727"},{"product_id":"egfp-pa4t-bhn20152452","title":"EGFP-PA4T","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eEGFP-PA4T\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239631970669,"sku":"IR0007002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239642194285,"sku":"IR0007010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239642227053,"sku":"IR0007020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239642259821,"sku":"IR0007050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239642292589,"sku":"IR0007100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239642325357,"sku":"IR0007500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_c9ad6e5b-f9a9-4f7c-b117-33a0b3238e9b.png?v=1776677729"},{"product_id":"tnf-bhn20152523","title":"TNF","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eTNF\u003c\/strong\u003e, a cytokines construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCytokines are a broad class of small secreted proteins that mediate intercellular communication within the immune system and across a range of tissue types. They include interleukins (ILs), interferons (IFNs), tumour necrosis factors (TNFs), and colony-stimulating factors (CSFs), each acting through cognate receptors to modulate immune activation, inflammation, haematopoiesis, and cell survival. mRNA-encoded cytokines are increasingly employed in immuno-oncology research as reference standards for neutralisation assays, antibody validation, receptor-binding studies, and bioassay development. Transient cytokine expression via mRNA avoids the chromosomal integration concerns associated with viral vector approaches and allows rapid, reversible functional evaluation.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eImmuno-oncology bioassay standards: Cytokine mRNAs expressed in reporter cell lines are used as reference materials for neutralising antibody potency assays and ELISA calibration in therapeutic antibody development.\u003c\/li\u003e\n  \u003cli\u003eCAR T-cell armoured constructs: mRNA-encoded cytokines (e.g., IL-15, IL-21) are being evaluated in combination with CAR constructs to improve T-cell persistence in solid tumour microenvironments.\u003c\/li\u003e\n  \u003cli\u003eInflammation modelling: Transient cytokine mRNA transfection allows controlled induction of inflammatory gene signatures in primary macrophages and dendritic cells for mechanistic pathway studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eNeutralisation assay standards — mRNA-expressed cytokines used as reference materials for potency and neutralisation testing of therapeutic antibodies in reporter-cell or bioassay formats.\u003c\/li\u003e\n  \u003cli\u003eReceptor binding validation — cell-surface expressed cytokine receptors or secreted cytokine ligands used in SPR, flow cytometry, and ELISA-based binding studies.\u003c\/li\u003e\n  \u003cli\u003eImmune cell activation studies — transient cytokine mRNA expression in primary immune cells (T cells, macrophages, NK cells) to dissect signalling pathways and transcriptional responses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCytokine secretion levels from transfected cells may vary with mRNA dose, cell type, and transfection efficiency; always quantify secreted protein by ELISA or bioassay before use as a standard.\u003c\/li\u003e\n  \u003cli\u003eFor neutralisation assays, confirm that the mRNA-expressed cytokine is biologically active (e.g., STAT signalling reporter) before using it as a reference antigen.\u003c\/li\u003e\n  \u003cli\u003eCytokine-encoding mRNAs can activate innate immune pathways in sensitive primary cells despite N1-Me-Pseudo UTP modification; include matched negative control mRNA (e.g., EGFP mRNA) at equivalent doses.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632036205,"sku":"IR0078002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239645536621,"sku":"IR0078010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239645569389,"sku":"IR0078020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239645602157,"sku":"IR0078050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239645634925,"sku":"IR0078100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239645667693,"sku":"IR0078500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_aa40da3b-a272-4ac7-9873-9d7dd31eec88.png?v=1776677730"},{"product_id":"firefly-luciferase-pa4t-bhn20152456","title":"Firefly Luciferase-PA4T","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eFirefly Luciferase-PA4T\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632003437,"sku":"IR0011002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239637049709,"sku":"IR0011010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239637082477,"sku":"IR0011020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239637115245,"sku":"IR0011050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239637148013,"sku":"IR0011100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239637180781,"sku":"IR0011500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_78a31897-df6f-4aeb-be8a-36c5214c2c0b.png?v=1776677727"},{"product_id":"gaussia-luciferase-bhn20152461","title":"Gaussia Luciferase","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eGaussia Luciferase\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632068973,"sku":"IR0016002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239639015789,"sku":"IR0016010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239639048557,"sku":"IR0016020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239639081325,"sku":"IR0016050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239639114093,"sku":"IR0016100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239639146861,"sku":"IR0016500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_beb74ef8-80c2-470d-a8f9-5a454eb2881c.png?v=1776677730"},{"product_id":"cd19-bhn20152470","title":"CD19","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD19\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632101741,"sku":"IR0025002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239641473389,"sku":"IR0025010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239641506157,"sku":"IR0025020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239641538925,"sku":"IR0025050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239641571693,"sku":"IR0025100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239641604461,"sku":"IR0025500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_cc60bb77-91df-49fe-aa59-befe9c590e15.png?v=1776677727"},{"product_id":"cd82-bhn20152490","title":"CD82","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD82\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632134509,"sku":"IR0045002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239639343469,"sku":"IR0045010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239639376237,"sku":"IR0045020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239639409005,"sku":"IR0045050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239639441773,"sku":"IR0045100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239639474541,"sku":"IR0045500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_4a206b03-ca3b-4ab8-8a65-069d90c17298.png?v=1776677729"},{"product_id":"tacstd2-trop-bhn20152496","title":"TACSTD2 （TROP）","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eTACSTD2 （TROP）\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632167277,"sku":"IR0051002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239638196589,"sku":"IR0051010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239638229357,"sku":"IR0051020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239638262125,"sku":"IR0051050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239638294893,"sku":"IR0051100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239638327661,"sku":"IR0051500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_a1f4beae-4cde-45ea-bb74-a10df1b87264.png?v=1776677730"},{"product_id":"cd47-bhn20152502","title":"CD47","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD47\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632200045,"sku":"IR0057002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239641309549,"sku":"IR0057010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239641342317,"sku":"IR0057020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239641375085,"sku":"IR0057050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239641407853,"sku":"IR0057100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239641440621,"sku":"IR0057500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_e2eaba95-3299-4a4b-a4f7-88848468620b.png?v=1776677728"},{"product_id":"cre-bhn20152458","title":"Cre","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCre\u003c\/strong\u003e, a recombinase construct supplied for gene editing and genome engineering applications. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eSite-specific recombinases catalyse conservative DNA rearrangements between defined recombination sites, enabling precise excision, integration, or inversion of genetic elements without the requirement for homologous sequences. Cre recombinase, derived from bacteriophage P1, acts on 34-bp \u003cem\u003eloxP\u003c\/em\u003e recognition sequences to excise flanked (floxed) DNA segments or invert sequences in an orientation-dependent manner. Transient delivery of Cre as mRNA provides precise temporal control over recombination events, crucial for conditional gene knockout studies, lineage tracing experiments, and removal of selection cassettes in engineered cell lines, while avoiding the prolonged Cre expression associated with stable integrants that can cause cytotoxicity and off-target recombination at pseudo-\u003cem\u003eloxP\u003c\/em\u003e sites in the mammalian genome.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eConditional gene knockout models: Cre mRNA enables precise temporal activation of floxed alleles in cell culture models without the leaky expression often observed with inducible Cre systems.\u003c\/li\u003e\n  \u003cli\u003eSelection marker removal: Cre mRNA-mediated excision of floxed antibiotic resistance or selection cassettes from engineered cell lines streamlines the generation of clean expression constructs.\u003c\/li\u003e\n  \u003cli\u003eLineage tracing in ex vivo systems: Transient Cre mRNA delivery to mixed cell populations initiates heritable reporter activation in Cre-responsive lineage reporter cells, enabling clonal tracking.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eFloxed allele activation — transient Cre mRNA delivery to cells carrying loxP-flanked conditional alleles to initiate gene knockout or reporter activation.\u003c\/li\u003e\n  \u003cli\u003eConstruct clean-up — mRNA Cre delivery to remove floxed selection markers or unwanted sequences from engineered cell lines without sustained Cre toxicity.\u003c\/li\u003e\n  \u003cli\u003eLineage tracing — Cre mRNA activation of Rosa26 or equivalent reporter alleles in mixed cell populations for clonal lineage marking.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eConfirm loxP site integrity in the target cell line before Cre mRNA delivery; partial loxP deletions or inversions may lead to incomplete or aberrant recombination outcomes.\u003c\/li\u003e\n  \u003cli\u003eCre mRNA expression is transient (peak at 12–24 h); in cells with low recombination efficiency, a second mRNA transfection 48 h later may improve allele conversion rates.\u003c\/li\u003e\n  \u003cli\u003eMonitor for off-target Cre toxicity: sustained or overexpressed Cre can cause chromosomal rearrangements at cryptic pseudo-loxP sites; use the minimum effective mRNA dose.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632265581,"sku":"IR0013002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239644553581,"sku":"IR0013010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239644586349,"sku":"IR0013020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239644619117,"sku":"IR0013050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239644651885,"sku":"IR0013100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239644684653,"sku":"IR0013500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_944f6581-770b-47e0-ad68-5326548f1001.png?v=1776677731"},{"product_id":"gh-bhn20152529","title":"GH","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eGH\u003c\/strong\u003e, a growth factor construct supplied for cytokine and growth factor protein expression studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eGrowth factors are secreted or membrane-bound polypeptides that regulate cell proliferation, survival, differentiation, and migration by binding to specific cell-surface receptors and activating downstream signalling cascades (e.g., MAPK\/ERK, PI3K\/AKT, JAK\/STAT). mRNA-based delivery of growth factors enables transient, dose-controlled protein expression in target cells without the need for stable genomic integration. This approach is particularly relevant for ex vivo cell expansion protocols, stem cell differentiation studies, and functional receptor-ligand binding assays, where precise temporal control of growth factor availability is required.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eEx vivo cell manufacturing: Transient mRNA expression of growth factors such as SCF, FLT3L, and TPO is being investigated for short-window stimulation of HSC expansion without chronic cytokine exposure that risks differentiation bias.\u003c\/li\u003e\n  \u003cli\u003eReceptor-ligand interaction studies: Growth factor mRNA provides native-topology ligands for SPR, BLI, and cell-based binding assays validating therapeutic antibody epitopes on receptor ectodomains.\u003c\/li\u003e\n  \u003cli\u003eTissue engineering scaffolds: Growth factor mRNA is incorporated into hydrogel and scaffold matrices to achieve controlled spatiotemporal protein release in tissue-regeneration models.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReceptor activation assays — transient growth factor mRNA expression stimulates cognate receptors in cell-based reporter assays to characterise ligand-receptor interactions.\u003c\/li\u003e\n  \u003cli\u003eEx vivo cell expansion — short-duration growth factor mRNA pulses to stimulate haematopoietic or stem cell expansion without chronic cytokine exposure.\u003c\/li\u003e\n  \u003cli\u003eAntibody neutralisation studies — mRNA-expressed secreted growth factors as target antigens in neutralisation bioassays validating anti-growth-factor therapeutic antibodies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSecreted growth factors expressed from transfected cells are present in conditioned media; ensure downstream assays account for the actual secreted protein concentration rather than mRNA input dose.\u003c\/li\u003e\n  \u003cli\u003eGrowth factor receptor expression on the target cell must be confirmed; absence of receptor expression on the transfected cell line may result in undetectable signalling readouts.\u003c\/li\u003e\n  \u003cli\u003eTransient expression windows are typically 24–72 h post-transfection for lyophilised mRNA; titrate dose and time-point empirically for the specific growth factor and cell type.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632232813,"sku":"IR0084002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239651697005,"sku":"IR0084010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239651729773,"sku":"IR0084020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239651762541,"sku":"IR0084050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239651795309,"sku":"IR0084100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239651828077,"sku":"IR0084500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_3b93fe94-23e4-45fc-a467-ec8a53628e95.png?v=1776677731"},{"product_id":"mcherry-renilla-bhn20152447","title":"mCherry-Renilla","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003emCherry-Renilla\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632298349,"sku":"IR0002002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239635902829,"sku":"IR0002010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239635935597,"sku":"IR0002020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239635968365,"sku":"IR0002050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239636001133,"sku":"IR0002100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239636033901,"sku":"IR0002500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_b9786c3f-3ea5-4c31-bbc4-808600ef8c3e.png?v=1776677730"},{"product_id":"cd38-bhn20152474","title":"CD38","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD38\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632363885,"sku":"IR0029002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239652516205,"sku":"IR0029010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239652548973,"sku":"IR0029020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239652581741,"sku":"IR0029050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239652614509,"sku":"IR0029100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239652647277,"sku":"IR0029500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_2a0db713-dd4d-4f54-bfdc-34ebf7a617c8.png?v=1776677730"},{"product_id":"vegfr2-kdr-bhn20152479","title":"VEGFR2 (KDR)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eVEGFR2 (KDR)\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632396653,"sku":"IR0034002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239640326509,"sku":"IR0034010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239640359277,"sku":"IR0034020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239640392045,"sku":"IR0034050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239640424813,"sku":"IR0034100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239640457581,"sku":"IR0034500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_76120f44-7469-43ee-ba8c-e2bdec77530e.png?v=1776677731"},{"product_id":"fgf2-bhn20152528","title":"FGF2","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eFGF2\u003c\/strong\u003e, a growth factor construct supplied for cytokine and growth factor protein expression studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eGrowth factors are secreted or membrane-bound polypeptides that regulate cell proliferation, survival, differentiation, and migration by binding to specific cell-surface receptors and activating downstream signalling cascades (e.g., MAPK\/ERK, PI3K\/AKT, JAK\/STAT). mRNA-based delivery of growth factors enables transient, dose-controlled protein expression in target cells without the need for stable genomic integration. This approach is particularly relevant for ex vivo cell expansion protocols, stem cell differentiation studies, and functional receptor-ligand binding assays, where precise temporal control of growth factor availability is required.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eEx vivo cell manufacturing: Transient mRNA expression of growth factors such as SCF, FLT3L, and TPO is being investigated for short-window stimulation of HSC expansion without chronic cytokine exposure that risks differentiation bias.\u003c\/li\u003e\n  \u003cli\u003eReceptor-ligand interaction studies: Growth factor mRNA provides native-topology ligands for SPR, BLI, and cell-based binding assays validating therapeutic antibody epitopes on receptor ectodomains.\u003c\/li\u003e\n  \u003cli\u003eTissue engineering scaffolds: Growth factor mRNA is incorporated into hydrogel and scaffold matrices to achieve controlled spatiotemporal protein release in tissue-regeneration models.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReceptor activation assays — transient growth factor mRNA expression stimulates cognate receptors in cell-based reporter assays to characterise ligand-receptor interactions.\u003c\/li\u003e\n  \u003cli\u003eEx vivo cell expansion — short-duration growth factor mRNA pulses to stimulate haematopoietic or stem cell expansion without chronic cytokine exposure.\u003c\/li\u003e\n  \u003cli\u003eAntibody neutralisation studies — mRNA-expressed secreted growth factors as target antigens in neutralisation bioassays validating anti-growth-factor therapeutic antibodies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSecreted growth factors expressed from transfected cells are present in conditioned media; ensure downstream assays account for the actual secreted protein concentration rather than mRNA input dose.\u003c\/li\u003e\n  \u003cli\u003eGrowth factor receptor expression on the target cell must be confirmed; absence of receptor expression on the transfected cell line may result in undetectable signalling readouts.\u003c\/li\u003e\n  \u003cli\u003eTransient expression windows are typically 24–72 h post-transfection for lyophilised mRNA; titrate dose and time-point empirically for the specific growth factor and cell type.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632429421,"sku":"IR0083002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239649829229,"sku":"IR0083010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239649861997,"sku":"IR0083020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239649894765,"sku":"IR0083050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239649927533,"sku":"IR0083100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239649960301,"sku":"IR0083500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_c1cdf14b-3008-433a-9a8b-2da16d3721ed.png?v=1776677729"},{"product_id":"her3-bhn20152498","title":"HER3","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eHER3\u003c\/strong\u003e, a membrane protein, tumor-associated antigens construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eTumour-associated antigens (TAAs) are proteins overexpressed or aberrantly presented on malignant cells compared to normal tissue, making them attractive targets for immunotherapy including CAR T-cell therapy, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs). Delivering TAA-encoding mRNA allows transient surface expression of the native antigen in human cell lines, supporting antibody epitope mapping, CAR construct validation, and target density quantification by flow cytometry. This format is particularly useful in early-stage target engagement studies where stable cell line generation would be time-prohibitive.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target density optimisation: mRNA dose titration enables construction of a target density gradient on cell surfaces, allowing measurement of CAR T-cell activation thresholds.\u003c\/li\u003e\n  \u003cli\u003eADC payload efficiency: Surface antigen expression via mRNA in cytotoxicity reporter cells supports evaluation of ADC internalisation efficiency and payload release kinetics.\u003c\/li\u003e\n  \u003cli\u003eBispecific T-cell engager (BiTE) studies: TAA mRNA-expressing target cells are used in BiTE-mediated T-cell redirected killing assays to determine antibody concentration-activity relationships.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T activation threshold studies — titrated mRNA expression creates antigen density gradients to determine the minimum antigen density required for CAR T-cell activation.\u003c\/li\u003e\n  \u003cli\u003eADC internalisation assays — mRNA-expressed TAA enables quantification of antibody internalisation rates essential for ADC payload delivery efficiency studies.\u003c\/li\u003e\n  \u003cli\u003eBiTE redirected killing assays — TAA-positive target cells support T-cell redirected killing measurement for bispecific T-cell engager dose-response characterisation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eValidate target antigen surface expression by flow cytometry with a clinically relevant antibody clone before using in CAR T functional assays to confirm antigen density is within the expected therapeutic range.\u003c\/li\u003e\n  \u003cli\u003eGPC3, PSMA, and HER3 may undergo post-translational modifications (N-glycosylation, GPI anchor addition) in the expression cell line; choose a cell line with the relevant processing machinery for the intended assay.\u003c\/li\u003e\n  \u003cli\u003eInclude antigen-negative control cells (same cell line, non-target mRNA transfected) in all killing and binding assays to distinguish antigen-specific from bystander activity.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632462189,"sku":"IR0053002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239637377389,"sku":"IR0053010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239637410157,"sku":"IR0053020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239637442925,"sku":"IR0053050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239637475693,"sku":"IR0053100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239637508461,"sku":"IR0053500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_7a12efe8-8b7d-42a0-a022-4f09e8abdaec.png?v=1776677730"},{"product_id":"tim3-bhn20152501","title":"TIM3","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eTIM3\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632494957,"sku":"IR0056002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239640490349,"sku":"IR0056010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239640523117,"sku":"IR0056020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239640555885,"sku":"IR0056050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239640588653,"sku":"IR0056100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239640621421,"sku":"IR0056500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_7a4b9b64-dafb-44db-830f-565de5cc1c5d.png?v=1776677732"},{"product_id":"met-bhn20152487","title":"MET","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eMET\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632527725,"sku":"IR0042002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239646191981,"sku":"IR0042010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239646224749,"sku":"IR0042020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239646257517,"sku":"IR0042050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239646290285,"sku":"IR0042100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239646323053,"sku":"IR0042500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_5f963f4a-5452-4ec1-bc62-683492913990.png?v=1776677729"},{"product_id":"tslp-bhn20152512","title":"TSLP","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eTSLP\u003c\/strong\u003e, a cytokines construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCytokines are a broad class of small secreted proteins that mediate intercellular communication within the immune system and across a range of tissue types. They include interleukins (ILs), interferons (IFNs), tumour necrosis factors (TNFs), and colony-stimulating factors (CSFs), each acting through cognate receptors to modulate immune activation, inflammation, haematopoiesis, and cell survival. mRNA-encoded cytokines are increasingly employed in immuno-oncology research as reference standards for neutralisation assays, antibody validation, receptor-binding studies, and bioassay development. Transient cytokine expression via mRNA avoids the chromosomal integration concerns associated with viral vector approaches and allows rapid, reversible functional evaluation.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eImmuno-oncology bioassay standards: Cytokine mRNAs expressed in reporter cell lines are used as reference materials for neutralising antibody potency assays and ELISA calibration in therapeutic antibody development.\u003c\/li\u003e\n  \u003cli\u003eCAR T-cell armoured constructs: mRNA-encoded cytokines (e.g., IL-15, IL-21) are being evaluated in combination with CAR constructs to improve T-cell persistence in solid tumour microenvironments.\u003c\/li\u003e\n  \u003cli\u003eInflammation modelling: Transient cytokine mRNA transfection allows controlled induction of inflammatory gene signatures in primary macrophages and dendritic cells for mechanistic pathway studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eNeutralisation assay standards — mRNA-expressed cytokines used as reference materials for potency and neutralisation testing of therapeutic antibodies in reporter-cell or bioassay formats.\u003c\/li\u003e\n  \u003cli\u003eReceptor binding validation — cell-surface expressed cytokine receptors or secreted cytokine ligands used in SPR, flow cytometry, and ELISA-based binding studies.\u003c\/li\u003e\n  \u003cli\u003eImmune cell activation studies — transient cytokine mRNA expression in primary immune cells (T cells, macrophages, NK cells) to dissect signalling pathways and transcriptional responses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCytokine secretion levels from transfected cells may vary with mRNA dose, cell type, and transfection efficiency; always quantify secreted protein by ELISA or bioassay before use as a standard.\u003c\/li\u003e\n  \u003cli\u003eFor neutralisation assays, confirm that the mRNA-expressed cytokine is biologically active (e.g., STAT signalling reporter) before using it as a reference antigen.\u003c\/li\u003e\n  \u003cli\u003eCytokine-encoding mRNAs can activate innate immune pathways in sensitive primary cells despite N1-Me-Pseudo UTP modification; include matched negative control mRNA (e.g., EGFP mRNA) at equivalent doses.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632560493,"sku":"IR0067002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239646519661,"sku":"IR0067010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239646552429,"sku":"IR0067020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239646585197,"sku":"IR0067050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239646617965,"sku":"IR0067100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239646650733,"sku":"IR0067500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_8c34b5a0-6caa-4388-a636-ab3c77985086.png?v=1776677729"},{"product_id":"cd3d-bhn20152465","title":"CD3D","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD3D\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632593261,"sku":"IR0020002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239636230509,"sku":"IR0020010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239636263277,"sku":"IR0020020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239636296045,"sku":"IR0020050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239636328813,"sku":"IR0020100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239636361581,"sku":"IR0020500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_0b309ecb-d6c4-4f3d-86a4-171fd1edeca7.png?v=1776677729"},{"product_id":"lta-bhn20152542","title":"LTA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eLTA\u003c\/strong\u003e, a cytokines construct supplied for cytokine and growth factor protein expression studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCytokines are a broad class of small secreted proteins that mediate intercellular communication within the immune system and across a range of tissue types. They include interleukins (ILs), interferons (IFNs), tumour necrosis factors (TNFs), and colony-stimulating factors (CSFs), each acting through cognate receptors to modulate immune activation, inflammation, haematopoiesis, and cell survival. mRNA-encoded cytokines are increasingly employed in immuno-oncology research as reference standards for neutralisation assays, antibody validation, receptor-binding studies, and bioassay development. Transient cytokine expression via mRNA avoids the chromosomal integration concerns associated with viral vector approaches and allows rapid, reversible functional evaluation.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eImmuno-oncology bioassay standards: Cytokine mRNAs expressed in reporter cell lines are used as reference materials for neutralising antibody potency assays and ELISA calibration in therapeutic antibody development.\u003c\/li\u003e\n  \u003cli\u003eCAR T-cell armoured constructs: mRNA-encoded cytokines (e.g., IL-15, IL-21) are being evaluated in combination with CAR constructs to improve T-cell persistence in solid tumour microenvironments.\u003c\/li\u003e\n  \u003cli\u003eInflammation modelling: Transient cytokine mRNA transfection allows controlled induction of inflammatory gene signatures in primary macrophages and dendritic cells for mechanistic pathway studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eNeutralisation assay standards — mRNA-expressed cytokines used as reference materials for potency and neutralisation testing of therapeutic antibodies in reporter-cell or bioassay formats.\u003c\/li\u003e\n  \u003cli\u003eReceptor binding validation — cell-surface expressed cytokine receptors or secreted cytokine ligands used in SPR, flow cytometry, and ELISA-based binding studies.\u003c\/li\u003e\n  \u003cli\u003eImmune cell activation studies — transient cytokine mRNA expression in primary immune cells (T cells, macrophages, NK cells) to dissect signalling pathways and transcriptional responses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCytokine secretion levels from transfected cells may vary with mRNA dose, cell type, and transfection efficiency; always quantify secreted protein by ELISA or bioassay before use as a standard.\u003c\/li\u003e\n  \u003cli\u003eFor neutralisation assays, confirm that the mRNA-expressed cytokine is biologically active (e.g., STAT signalling reporter) before using it as a reference antigen.\u003c\/li\u003e\n  \u003cli\u003eCytokine-encoding mRNAs can activate innate immune pathways in sensitive primary cells despite N1-Me-Pseudo UTP modification; include matched negative control mRNA (e.g., EGFP mRNA) at equivalent doses.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632626029,"sku":"IR0097002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239640654189,"sku":"IR0097010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239640686957,"sku":"IR0097020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239640719725,"sku":"IR0097050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239640752493,"sku":"IR0097100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239640785261,"sku":"IR0097500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_adc287dd-a0ce-4068-ae2b-555a2733c5ae.png?v=1776677730"},{"product_id":"egf-bhn20152532","title":"EGF","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eEGF\u003c\/strong\u003e, a growth factor construct supplied for cytokine and growth factor protein expression studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eGrowth factors are secreted or membrane-bound polypeptides that regulate cell proliferation, survival, differentiation, and migration by binding to specific cell-surface receptors and activating downstream signalling cascades (e.g., MAPK\/ERK, PI3K\/AKT, JAK\/STAT). mRNA-based delivery of growth factors enables transient, dose-controlled protein expression in target cells without the need for stable genomic integration. This approach is particularly relevant for ex vivo cell expansion protocols, stem cell differentiation studies, and functional receptor-ligand binding assays, where precise temporal control of growth factor availability is required.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eEx vivo cell manufacturing: Transient mRNA expression of growth factors such as SCF, FLT3L, and TPO is being investigated for short-window stimulation of HSC expansion without chronic cytokine exposure that risks differentiation bias.\u003c\/li\u003e\n  \u003cli\u003eReceptor-ligand interaction studies: Growth factor mRNA provides native-topology ligands for SPR, BLI, and cell-based binding assays validating therapeutic antibody epitopes on receptor ectodomains.\u003c\/li\u003e\n  \u003cli\u003eTissue engineering scaffolds: Growth factor mRNA is incorporated into hydrogel and scaffold matrices to achieve controlled spatiotemporal protein release in tissue-regeneration models.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReceptor activation assays — transient growth factor mRNA expression stimulates cognate receptors in cell-based reporter assays to characterise ligand-receptor interactions.\u003c\/li\u003e\n  \u003cli\u003eEx vivo cell expansion — short-duration growth factor mRNA pulses to stimulate haematopoietic or stem cell expansion without chronic cytokine exposure.\u003c\/li\u003e\n  \u003cli\u003eAntibody neutralisation studies — mRNA-expressed secreted growth factors as target antigens in neutralisation bioassays validating anti-growth-factor therapeutic antibodies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSecreted growth factors expressed from transfected cells are present in conditioned media; ensure downstream assays account for the actual secreted protein concentration rather than mRNA input dose.\u003c\/li\u003e\n  \u003cli\u003eGrowth factor receptor expression on the target cell must be confirmed; absence of receptor expression on the transfected cell line may result in undetectable signalling readouts.\u003c\/li\u003e\n  \u003cli\u003eTransient expression windows are typically 24–72 h post-transfection for lyophilised mRNA; titrate dose and time-point empirically for the specific growth factor and cell type.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632658797,"sku":"IR0087002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239640162669,"sku":"IR0087010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239640195437,"sku":"IR0087020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239640228205,"sku":"IR0087050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239640260973,"sku":"IR0087100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239640293741,"sku":"IR0087500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_b577c457-277d-4310-8af5-149bab0fbbf9.png?v=1776677730"},{"product_id":"il6-bhn20152519","title":"IL6","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eIL6\u003c\/strong\u003e, a cytokines construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCytokines are a broad class of small secreted proteins that mediate intercellular communication within the immune system and across a range of tissue types. They include interleukins (ILs), interferons (IFNs), tumour necrosis factors (TNFs), and colony-stimulating factors (CSFs), each acting through cognate receptors to modulate immune activation, inflammation, haematopoiesis, and cell survival. mRNA-encoded cytokines are increasingly employed in immuno-oncology research as reference standards for neutralisation assays, antibody validation, receptor-binding studies, and bioassay development. Transient cytokine expression via mRNA avoids the chromosomal integration concerns associated with viral vector approaches and allows rapid, reversible functional evaluation.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eImmuno-oncology bioassay standards: Cytokine mRNAs expressed in reporter cell lines are used as reference materials for neutralising antibody potency assays and ELISA calibration in therapeutic antibody development.\u003c\/li\u003e\n  \u003cli\u003eCAR T-cell armoured constructs: mRNA-encoded cytokines (e.g., IL-15, IL-21) are being evaluated in combination with CAR constructs to improve T-cell persistence in solid tumour microenvironments.\u003c\/li\u003e\n  \u003cli\u003eInflammation modelling: Transient cytokine mRNA transfection allows controlled induction of inflammatory gene signatures in primary macrophages and dendritic cells for mechanistic pathway studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eNeutralisation assay standards — mRNA-expressed cytokines used as reference materials for potency and neutralisation testing of therapeutic antibodies in reporter-cell or bioassay formats.\u003c\/li\u003e\n  \u003cli\u003eReceptor binding validation — cell-surface expressed cytokine receptors or secreted cytokine ligands used in SPR, flow cytometry, and ELISA-based binding studies.\u003c\/li\u003e\n  \u003cli\u003eImmune cell activation studies — transient cytokine mRNA expression in primary immune cells (T cells, macrophages, NK cells) to dissect signalling pathways and transcriptional responses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCytokine secretion levels from transfected cells may vary with mRNA dose, cell type, and transfection efficiency; always quantify secreted protein by ELISA or bioassay before use as a standard.\u003c\/li\u003e\n  \u003cli\u003eFor neutralisation assays, confirm that the mRNA-expressed cytokine is biologically active (e.g., STAT signalling reporter) before using it as a reference antigen.\u003c\/li\u003e\n  \u003cli\u003eCytokine-encoding mRNAs can activate innate immune pathways in sensitive primary cells despite N1-Me-Pseudo UTP modification; include matched negative control mRNA (e.g., EGFP mRNA) at equivalent doses.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632691565,"sku":"IR0074002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239648846189,"sku":"IR0074010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239648878957,"sku":"IR0074020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239648911725,"sku":"IR0074050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239648944493,"sku":"IR0074100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239648977261,"sku":"IR0074500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_6a0bbae8-8136-4859-b1b9-8837d59d08e7.png?v=1776677729"},{"product_id":"psma-folh1-bhn20152503","title":"PSMA (FOLH1)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003ePSMA (FOLH1)\u003c\/strong\u003e, a membrane protein, tumor-associated antigens construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eTumour-associated antigens (TAAs) are proteins overexpressed or aberrantly presented on malignant cells compared to normal tissue, making them attractive targets for immunotherapy including CAR T-cell therapy, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs). Delivering TAA-encoding mRNA allows transient surface expression of the native antigen in human cell lines, supporting antibody epitope mapping, CAR construct validation, and target density quantification by flow cytometry. This format is particularly useful in early-stage target engagement studies where stable cell line generation would be time-prohibitive.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target density optimisation: mRNA dose titration enables construction of a target density gradient on cell surfaces, allowing measurement of CAR T-cell activation thresholds.\u003c\/li\u003e\n  \u003cli\u003eADC payload efficiency: Surface antigen expression via mRNA in cytotoxicity reporter cells supports evaluation of ADC internalisation efficiency and payload release kinetics.\u003c\/li\u003e\n  \u003cli\u003eBispecific T-cell engager (BiTE) studies: TAA mRNA-expressing target cells are used in BiTE-mediated T-cell redirected killing assays to determine antibody concentration-activity relationships.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T activation threshold studies — titrated mRNA expression creates antigen density gradients to determine the minimum antigen density required for CAR T-cell activation.\u003c\/li\u003e\n  \u003cli\u003eADC internalisation assays — mRNA-expressed TAA enables quantification of antibody internalisation rates essential for ADC payload delivery efficiency studies.\u003c\/li\u003e\n  \u003cli\u003eBiTE redirected killing assays — TAA-positive target cells support T-cell redirected killing measurement for bispecific T-cell engager dose-response characterisation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eValidate target antigen surface expression by flow cytometry with a clinically relevant antibody clone before using in CAR T functional assays to confirm antigen density is within the expected therapeutic range.\u003c\/li\u003e\n  \u003cli\u003eGPC3, PSMA, and HER3 may undergo post-translational modifications (N-glycosylation, GPI anchor addition) in the expression cell line; choose a cell line with the relevant processing machinery for the intended assay.\u003c\/li\u003e\n  \u003cli\u003eInclude antigen-negative control cells (same cell line, non-target mRNA transfected) in all killing and binding assays to distinguish antigen-specific from bystander activity.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632724333,"sku":"IR0058002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239638851949,"sku":"IR0058010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239638884717,"sku":"IR0058020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239638917485,"sku":"IR0058050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239638950253,"sku":"IR0058100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239638983021,"sku":"IR0058500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_6d979d31-67a1-4ab5-b50b-b4bc7bbc0987.png?v=1776677729"},{"product_id":"claudin-18-2-bhn20152499","title":"Claudin 18.2","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eClaudin 18.2\u003c\/strong\u003e, a membrane protein, tumor-associated antigens construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eTumour-associated antigens (TAAs) are proteins overexpressed or aberrantly presented on malignant cells compared to normal tissue, making them attractive targets for immunotherapy including CAR T-cell therapy, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs). Delivering TAA-encoding mRNA allows transient surface expression of the native antigen in human cell lines, supporting antibody epitope mapping, CAR construct validation, and target density quantification by flow cytometry. This format is particularly useful in early-stage target engagement studies where stable cell line generation would be time-prohibitive.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target density optimisation: mRNA dose titration enables construction of a target density gradient on cell surfaces, allowing measurement of CAR T-cell activation thresholds.\u003c\/li\u003e\n  \u003cli\u003eADC payload efficiency: Surface antigen expression via mRNA in cytotoxicity reporter cells supports evaluation of ADC internalisation efficiency and payload release kinetics.\u003c\/li\u003e\n  \u003cli\u003eBispecific T-cell engager (BiTE) studies: TAA mRNA-expressing target cells are used in BiTE-mediated T-cell redirected killing assays to determine antibody concentration-activity relationships.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T activation threshold studies — titrated mRNA expression creates antigen density gradients to determine the minimum antigen density required for CAR T-cell activation.\u003c\/li\u003e\n  \u003cli\u003eADC internalisation assays — mRNA-expressed TAA enables quantification of antibody internalisation rates essential for ADC payload delivery efficiency studies.\u003c\/li\u003e\n  \u003cli\u003eBiTE redirected killing assays — TAA-positive target cells support T-cell redirected killing measurement for bispecific T-cell engager dose-response characterisation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eValidate target antigen surface expression by flow cytometry with a clinically relevant antibody clone before using in CAR T functional assays to confirm antigen density is within the expected therapeutic range.\u003c\/li\u003e\n  \u003cli\u003eGPC3, PSMA, and HER3 may undergo post-translational modifications (N-glycosylation, GPI anchor addition) in the expression cell line; choose a cell line with the relevant processing machinery for the intended assay.\u003c\/li\u003e\n  \u003cli\u003eInclude antigen-negative control cells (same cell line, non-target mRNA transfected) in all killing and binding assays to distinguish antigen-specific from bystander activity.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632757101,"sku":"IR0054002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239647338861,"sku":"IR0054010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239647371629,"sku":"IR0054020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239647404397,"sku":"IR0054050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239647437165,"sku":"IR0054100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239647469933,"sku":"IR0054500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA.png?v=1776677726"},{"product_id":"mcherry-pa4t-bhn20152454","title":"mCherry-PA4T","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003emCherry-PA4T\u003c\/strong\u003e, a reporter gene construct supplied for mRNA delivery tracing and transfection efficiency studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eReporter proteins are widely used in molecular and cell biology as observable readouts for gene expression, mRNA delivery efficiency, and intracellular trafficking. Fluorescent proteins such as EGFP, mCherry, and their derivatives emit detectable signals under specific excitation wavelengths, enabling real-time live-cell imaging and quantitative flow cytometry. Bioluminescent reporters, including Firefly luciferase (Fluc) and \u003cem\u003eRenilla\u003c\/em\u003e luciferase, catalyse light-producing reactions that allow highly sensitive detection in plate-based assays with minimal background. Reporter mRNAs are particularly valuable for benchmarking lipid nanoparticle (LNP) formulations, electroporation parameters, and transfection reagents before transitioning to therapeutically relevant cargo.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery benchmarking: Reporter mRNAs are used as surrogate payloads to rapidly optimise LNP formulations, electroporation parameters, and transfection reagent doses before committing costly therapeutic cargo to delivery trials.\u003c\/li\u003e\n  \u003cli\u003eOrthogonal dual-reporter assays: EGFP\/mCherry + Firefly\/Renilla dual-reporter mRNA pairs allow internal normalisation of delivery efficiency versus transcriptional output in the same cell population.\u003c\/li\u003e\n  \u003cli\u003eCircular RNA reporters: circRNA-based reporter constructs (e.g., circEGFP, circFluc) are being explored as longer-lived, cap-independent expression platforms compared to conventional linear mRNA, with resistance to cellular 5′–3′ exonucleases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003emRNA delivery efficiency benchmarking — measuring fluorescence or bioluminescence as surrogate readout for payload delivery and expression kinetics across formulations.\u003c\/li\u003e\n  \u003cli\u003eTransfection optimisation — titrating reagent dose, mRNA concentration, and time-points using rapidly detectable reporter signals before transitioning to functional payloads.\u003c\/li\u003e\n  \u003cli\u003eIntracellular tracking — live-cell imaging with fluorescent reporter mRNAs to monitor subcellular localisation and translation dynamics in real time.\u003c\/li\u003e\n  \u003cli\u003eDual-reporter normalisation — paired reporter constructs (e.g., EGFP-Fluc, mCherry-Renilla) provide internal controls for delivery efficiency versus expression output.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eReporter signal intensity varies with transfection efficiency, cell health, and mRNA dose; include an untransfected negative control and a parallel positive control at all time-points.\u003c\/li\u003e\n  \u003cli\u003eFluorescent reporter mRNAs (EGFP, mCherry) express within 4–6 h post-transfection; bioluminescent reporters (Fluc, Renilla) typically reach peak signal 12–24 h post-transfection depending on substrate availability.\u003c\/li\u003e\n  \u003cli\u003ePA4T- and PA-tagged variants include additional protein sequences that may affect fluorescence intensity or antibody detection; confirm variant compatibility with downstream detection methods before use.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632822637,"sku":"IR0009002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239642030445,"sku":"IR0009010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239642063213,"sku":"IR0009020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239642095981,"sku":"IR0009050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239642128749,"sku":"IR0009100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239642161517,"sku":"IR0009500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_bdeaa9d8-5570-4932-b45d-e37551e78211.png?v=1776677726"},{"product_id":"cd48-bhn20152475","title":"CD48","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD48\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632789869,"sku":"IR0030002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239635738989,"sku":"IR0030010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239635771757,"sku":"IR0030020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239635804525,"sku":"IR0030050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239635837293,"sku":"IR0030100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239635870061,"sku":"IR0030500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_383616d5-e0bc-4d38-a2d4-6c9fd630dea3.png?v=1776677730"},{"product_id":"il4-bhn20152517","title":"IL4","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eIL4\u003c\/strong\u003e, a cytokines construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCytokines are a broad class of small secreted proteins that mediate intercellular communication within the immune system and across a range of tissue types. They include interleukins (ILs), interferons (IFNs), tumour necrosis factors (TNFs), and colony-stimulating factors (CSFs), each acting through cognate receptors to modulate immune activation, inflammation, haematopoiesis, and cell survival. mRNA-encoded cytokines are increasingly employed in immuno-oncology research as reference standards for neutralisation assays, antibody validation, receptor-binding studies, and bioassay development. Transient cytokine expression via mRNA avoids the chromosomal integration concerns associated with viral vector approaches and allows rapid, reversible functional evaluation.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eImmuno-oncology bioassay standards: Cytokine mRNAs expressed in reporter cell lines are used as reference materials for neutralising antibody potency assays and ELISA calibration in therapeutic antibody development.\u003c\/li\u003e\n  \u003cli\u003eCAR T-cell armoured constructs: mRNA-encoded cytokines (e.g., IL-15, IL-21) are being evaluated in combination with CAR constructs to improve T-cell persistence in solid tumour microenvironments.\u003c\/li\u003e\n  \u003cli\u003eInflammation modelling: Transient cytokine mRNA transfection allows controlled induction of inflammatory gene signatures in primary macrophages and dendritic cells for mechanistic pathway studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eNeutralisation assay standards — mRNA-expressed cytokines used as reference materials for potency and neutralisation testing of therapeutic antibodies in reporter-cell or bioassay formats.\u003c\/li\u003e\n  \u003cli\u003eReceptor binding validation — cell-surface expressed cytokine receptors or secreted cytokine ligands used in SPR, flow cytometry, and ELISA-based binding studies.\u003c\/li\u003e\n  \u003cli\u003eImmune cell activation studies — transient cytokine mRNA expression in primary immune cells (T cells, macrophages, NK cells) to dissect signalling pathways and transcriptional responses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCytokine secretion levels from transfected cells may vary with mRNA dose, cell type, and transfection efficiency; always quantify secreted protein by ELISA or bioassay before use as a standard.\u003c\/li\u003e\n  \u003cli\u003eFor neutralisation assays, confirm that the mRNA-expressed cytokine is biologically active (e.g., STAT signalling reporter) before using it as a reference antigen.\u003c\/li\u003e\n  \u003cli\u003eCytokine-encoding mRNAs can activate innate immune pathways in sensitive primary cells despite N1-Me-Pseudo UTP modification; include matched negative control mRNA (e.g., EGFP mRNA) at equivalent doses.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632888173,"sku":"IR0072002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239650812269,"sku":"IR0072010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239650845037,"sku":"IR0072020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239650877805,"sku":"IR0072050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239650910573,"sku":"IR0072100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239650943341,"sku":"IR0072500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_f63bb87c-7d92-49fe-a980-ea59718d00fb.png?v=1776677731"},{"product_id":"sb100x-bhn20152548","title":"SB100X","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eSB100X\u003c\/strong\u003e, a transposase construct supplied for gene editing and genome engineering applications. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eTransposases are enzymes that catalyse the cut-and-paste (Class II) or copy-and-paste transposition of discrete DNA elements (transposons) into host genomes in a sequence-specific manner. Hyperactive Sleeping Beauty transposase (hyPBase) and Sleeping Beauty 100x (SB100X) are engineered variants of the \u003cem\u003eSalmo salar\u003c\/em\u003e Tc1\/mariner-family transposon system with substantially enhanced integration activity relative to the wild-type enzyme. Co-delivery of transposase mRNA with a donor plasmid carrying the transposon cargo offers a non-viral route to stable genomic integration, commonly employed in CAR T-cell manufacturing, gene therapy research, and stable cell line generation where viral vector capacity or safety restrictions limit alternative approaches.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eNon-viral CAR T manufacturing: Sleeping Beauty transposon systems with hyperactive transposase mRNA are in clinical-stage evaluation for cost-effective, GMP-compatible stable CAR integration into T cells.\u003c\/li\u003e\n  \u003cli\u003eStable reporter cell generation: Transposase mRNA + transposon plasmid co-delivery generates stable fluorescent or selection-marked cell lines without lentiviral handling constraints.\u003c\/li\u003e\n  \u003cli\u003eHigh-throughput genetic screen libraries: piggyBac (hyPBase) systems enable reversible, scarless transgene removal after selection due to transposon excision, supporting iterative genetic library strategies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eStable transgene integration — co-delivery of transposase mRNA with transposon donor plasmid for non-viral genomic integration of therapeutic or reporter constructs.\u003c\/li\u003e\n  \u003cli\u003eCAR T-cell manufacturing research — SB100X or hyPBase transposase mRNA in T-cell engineering studies for stable CAR expression without lentiviral production.\u003c\/li\u003e\n  \u003cli\u003eSelection cassette integration — stable antibiotic resistance marker insertion followed by transposase-mediated excision for scarless genetic modification.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eTransposase mRNA activity requires co-delivery of a compatible transposon plasmid carrying ITR sequences flanking the cargo; confirm ITR compatibility with the specific transposase variant used (SB- or piggyBac-specific ITRs are not interchangeable).\u003c\/li\u003e\n  \u003cli\u003eIntegration site distribution is semi-random for both SB and hyPBase systems; for applications requiring site-specific integration, confirm acceptable genomic safety profiles by integration site analysis.\u003c\/li\u003e\n  \u003cli\u003eStable cell selection (antibiotic or FACS) should begin 48–72 h post-transfection; delayed selection may reduce clonal yield from incomplete transposition events.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632855405,"sku":"IR0103002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239648158061,"sku":"IR0103010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239648190829,"sku":"IR0103020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239648223597,"sku":"IR0103050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239648256365,"sku":"IR0103100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239648289133,"sku":"IR0103500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_5c4b9e0e-fbcb-431b-826b-b736694d582b.png?v=1776677727"},{"product_id":"cd22-bhn20152472","title":"CD22","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD22\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632953709,"sku":"IR0027002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239645208941,"sku":"IR0027010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239645241709,"sku":"IR0027020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239645274477,"sku":"IR0027050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239645307245,"sku":"IR0027100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239645340013,"sku":"IR0027500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_c0830f89-a875-45b0-b405-b70cab02604d.png?v=1776677728"},{"product_id":"pdgfra-bhn20152488","title":"PDGFRA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003ePDGFRA\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239632986477,"sku":"IR0043002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239639179629,"sku":"IR0043010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239639212397,"sku":"IR0043020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239639245165,"sku":"IR0043050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239639277933,"sku":"IR0043100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239639310701,"sku":"IR0043500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_be8bb1f4-0a7e-46ff-890d-d2d60f777f80.png?v=1776677726"},{"product_id":"gprc5d-bhn20152500","title":"GPRC5D","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eGPRC5D\u003c\/strong\u003e, a membrane protein, tumor-associated antigens construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eTumour-associated antigens (TAAs) are proteins overexpressed or aberrantly presented on malignant cells compared to normal tissue, making them attractive targets for immunotherapy including CAR T-cell therapy, antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs). Delivering TAA-encoding mRNA allows transient surface expression of the native antigen in human cell lines, supporting antibody epitope mapping, CAR construct validation, and target density quantification by flow cytometry. This format is particularly useful in early-stage target engagement studies where stable cell line generation would be time-prohibitive.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target density optimisation: mRNA dose titration enables construction of a target density gradient on cell surfaces, allowing measurement of CAR T-cell activation thresholds.\u003c\/li\u003e\n  \u003cli\u003eADC payload efficiency: Surface antigen expression via mRNA in cytotoxicity reporter cells supports evaluation of ADC internalisation efficiency and payload release kinetics.\u003c\/li\u003e\n  \u003cli\u003eBispecific T-cell engager (BiTE) studies: TAA mRNA-expressing target cells are used in BiTE-mediated T-cell redirected killing assays to determine antibody concentration-activity relationships.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T activation threshold studies — titrated mRNA expression creates antigen density gradients to determine the minimum antigen density required for CAR T-cell activation.\u003c\/li\u003e\n  \u003cli\u003eADC internalisation assays — mRNA-expressed TAA enables quantification of antibody internalisation rates essential for ADC payload delivery efficiency studies.\u003c\/li\u003e\n  \u003cli\u003eBiTE redirected killing assays — TAA-positive target cells support T-cell redirected killing measurement for bispecific T-cell engager dose-response characterisation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eValidate target antigen surface expression by flow cytometry with a clinically relevant antibody clone before using in CAR T functional assays to confirm antigen density is within the expected therapeutic range.\u003c\/li\u003e\n  \u003cli\u003eGPC3, PSMA, and HER3 may undergo post-translational modifications (N-glycosylation, GPI anchor addition) in the expression cell line; choose a cell line with the relevant processing machinery for the intended assay.\u003c\/li\u003e\n  \u003cli\u003eInclude antigen-negative control cells (same cell line, non-target mRNA transfected) in all killing and binding assays to distinguish antigen-specific from bystander activity.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239633019245,"sku":"IR0055002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239636066669,"sku":"IR0055010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239636099437,"sku":"IR0055020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239636132205,"sku":"IR0055050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239636164973,"sku":"IR0055100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239636197741,"sku":"IR0055500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_d9e97a80-fc1a-41d9-bcd5-67272a02bd69.png?v=1776677730"},{"product_id":"her2-erbb2-bhn20152482","title":"HER2 (ERBB2)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eHER2 (ERBB2)\u003c\/strong\u003e, a membrane protein construct supplied for antibody screening, CAR T-cell target validation, and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239633052013,"sku":"IR0037002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239648321901,"sku":"IR0037010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239648354669,"sku":"IR0037020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239648387437,"sku":"IR0037050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239648420205,"sku":"IR0037100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239648452973,"sku":"IR0037500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_21b65727-f8c3-448d-9517-395a5475e646.png?v=1776677730"},{"product_id":"espcas9-bhn20152546","title":"eSpCas9","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eeSpCas9\u003c\/strong\u003e, a cas protein construct supplied for gene editing and genome engineering applications. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCRISPR-associated (Cas) proteins are programmable RNA-guided endonucleases derived from bacterial adaptive immune systems. Class 2 Cas nucleases, including the widely used \u003cem\u003eStreptococcus pyogenes\u003c\/em\u003e Cas9 (SpCas9) and the Cpf1 (Cas12a) orthologues from \u003cem\u003eAcidaminococcus\u003c\/em\u003e (AsCas12a\/AsCpf1) and \u003cem\u003eLachnospiraceae\u003c\/em\u003e (LbCas12a\/LbCpf1), introduce site-specific double-strand breaks guided by single guide RNA (sgRNA) or CRISPR RNA (crRNA). Delivery of Cas nuclease as mRNA rather than plasmid DNA reduces the risk of off-target genomic integration, restricts editing activity to the transient window of mRNA half-life, and minimises innate immune responses in primary cells, making mRNA-based CRISPR delivery increasingly preferred for therapeutic genome editing and ex vivo haematopoietic stem cell (HSC) modification.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eNon-integrating genome editing: Cas9 and Cas12a mRNA co-delivery with guide RNA (as synthetic crRNA:tracrRNA duplexes or sgRNA) achieves transient editing activity, reducing the off-target editing window compared to plasmid-based systems.\u003c\/li\u003e\n  \u003cli\u003eBase editing and prime editing: Modified Cas protein mRNAs (e.g., high-fidelity SpCas9 variants) serve as the nuclease backbone for base editors (CBEs\/ABEs) and prime editors, where mRNA delivery reduces immunogenicity and enables editing in post-mitotic cells.\u003c\/li\u003e\n  \u003cli\u003eClinical-grade HSC editing: Ex vivo haematopoietic stem cell editing programmes (e.g., for haemoglobinopathies) favour mRNA-RNP delivery for regulatory safety profiles in GMP-adjacent workflows.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eTransient genome editing — Cas9\/Cas12a mRNA co-delivery with guide RNA for site-directed insertions, deletions, or substitutions in primary cells and cell lines.\u003c\/li\u003e\n  \u003cli\u003eIndel analysis — mRNA-based editing followed by surveyor assay, Sanger sequencing, or NGS to quantify on-target editing efficiency at defined genomic loci.\u003c\/li\u003e\n  \u003cli\u003eBase editing and prime editing — Cas mRNA as the scaffold for base editor or prime editor fusion proteins for precise nucleotide conversions without double-strand breaks.\u003c\/li\u003e\n  \u003cli\u003eRNP optimisation — Cas protein mRNA-to-guide-RNA ratio titration to maximise editing efficiency while minimising cytotoxicity across cell types.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCas protein mRNA activity depends on guide RNA quality and design; evaluate multiple guide sequences across the target locus and confirm on-target editing by sequencing before committing to functional experiments.\u003c\/li\u003e\n  \u003cli\u003eHigh Cas9 mRNA doses can be cytotoxic, particularly in primary cells; titrate mRNA amount empirically and assess viability 24 h post-transfection before proceeding to editing analysis.\u003c\/li\u003e\n  \u003cli\u003eeSpCas9 (enhanced specificity variant) contains specific mutations (e.g., K848A\/K1003A\/R1060A) that reduce off-target activity; confirm the variant designation matches the intended specificity profile.\u003c\/li\u003e\n  \u003cli\u003eCas12a (Cpf1) orthologs have distinct PAM requirements (TTTV for LbCas12a; TTTV\/TTTT for AsCas12a); verify PAM compatibility at the target site before designing crRNA.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239633084781,"sku":"IR0101002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239639998829,"sku":"IR0101010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239640031597,"sku":"IR0101020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239640064365,"sku":"IR0101050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239640097133,"sku":"IR0101100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239640129901,"sku":"IR0101500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_fae889b1-5a2d-4f68-a5d6-858524792794.png?v=1776677729"},{"product_id":"cd3g-bhn20152464","title":"CD3G","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis GenCefe mRNA encodes \u003cstrong\u003eCD3G\u003c\/strong\u003e, a membrane protein construct supplied for antibody validation and cell-based binding assays. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.\u003c\/p\u003e\n\u003ch2\u003emRNA Construct Design\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ Cap:\u003c\/strong\u003e Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1\/IFIT3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModified Nucleotides:\u003c\/strong\u003e 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7\/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoly(A) Tail:\u003c\/strong\u003e 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3′ UTR:\u003c\/strong\u003e hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSignal Peptide:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein Tag:\u003c\/strong\u003e No\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCodon Optimisation:\u003c\/strong\u003e No (native human codon usage retained)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA Length:\u003c\/strong\u003e Provided upon order placement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder; reconstitute in DEPC-treated water as needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.\u003c\/p\u003e\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eCell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.\u003c\/p\u003e\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eCAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.\u003c\/li\u003e\n  \u003cli\u003eConformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAntibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.\u003c\/li\u003e\n  \u003cli\u003eCAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.\u003c\/li\u003e\n  \u003cli\u003eBispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eSurface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.\u003c\/li\u003e\n  \u003cli\u003eComplex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.\u003c\/li\u003e\n  \u003cli\u003eTransient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"GenCefe Biotech","offers":[{"title":"20 ug","offer_id":53239633117549,"sku":"IR0019002","price":279.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53239641637229,"sku":"IR0019010","price":339.0,"currency_code":"USD","in_stock":true},{"title":"200 ug","offer_id":53239641669997,"sku":"IR0019020","price":399.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":53239641702765,"sku":"IR0019050","price":459.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":53239641735533,"sku":"IR0019100","price":549.0,"currency_code":"USD","in_stock":true},{"title":"5 mg","offer_id":53239641768301,"sku":"IR0019500","price":1799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/mRNA_7feb7be8-8688-4fe4-91c9-5ef201ee9f2a.png?v=1776677730"}],"url":"https:\/\/www.ebiohippo.com\/collections\/mrna-reagents.oembed?page=3","provider":"BioHippo","version":"1.0","type":"link"}